Neurogene Inc (NGNE) Stock Price, Quote & News

Company Profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LL...

Industry: Biotechnology

Sector: Healthcare

Phone: 855 508 3568

Website: www.neurogene.com

Address:

535 W 24th Street, 5th Floor, New York, United States

Mkemovic23 Jul. 9 at 11:46 PM

$NGNE could get the breakout move tomorrow

0 · Reply

MisterRaymond Jul. 9 at 5:50 PM

$NGNE

0 · Reply

Mkemovic23 Jul. 9 at 4:34 PM

$NGNE guess I’ll just enjoy this move myself. 8 days, no posts here besides me. This company could easily run To 30-40 with very little effort and it probably will

0 · Reply

Mkemovic23 Jul. 8 at 4:33 PM

$NGNE great move today, let’s clear 21.8 and there is tremendous upside here … small number of watchers

0 · Reply

topstockalerts Jul. 1 at 7:49 PM

$NGNE Strong move today..👀---👀...

0 · Reply

hiloSF Jul. 1 at 7:26 PM

$NGNE facing a tough resistance zone right overhead 🤼🚧👷 👇🏽👇🏿 (Charted using Pro+ 👉 https://www.tradingview.com/?aff_id=1333 📈Not just charts. A full trading platform for serious traders! )

0 · Reply

topstockalerts Jul. 1 at 7:02 PM

$NGNE strong watch at these levels 👀💪👀

0 · Reply

FelipeLuis Jul. 1 at 6:36 PM

$NGNE Solid news. Can move in any direction anytime. $BGLC $BGL $BMNR

0 · Reply

FelipeLuis Jul. 1 at 6:29 PM

$NGNE Solid news. Just need to hold and wait

0 · Reply

Mkemovic23 Jul. 1 at 6:20 PM

$NGNE can be $30-40 in a blink of an eye, literally no float

0 · Reply

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:01 PM EDT - 12 days ago

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

May 16, 2025, 7:00 AM EDT - 2 months ago

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 9, 2025, 7:30 AM EDT - 2 months ago

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Apr 28, 2025, 5:00 PM EDT - 2 months ago

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Apr 2, 2025, 4:01 PM EDT - 3 months ago

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Mar 24, 2025, 4:10 PM EDT - 3 months ago

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Feb 24, 2025, 7:30 AM EST - 4 months ago

Neurogene to Participate in Upcoming Conferences

Nov 28, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Nov 27, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 8 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Nov 24, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Nov 22, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Nov 20, 2024, 10:00 AM EST - 8 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 18, 2024, 5:25 PM EST - 8 months ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Nov 18, 2024, 6:45 AM EST - 8 months ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 17, 2024, 10:00 AM EST - 8 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Nov 14, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Nov 13, 2024, 11:30 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Nov 12, 2024, 11:25 AM EST - 8 months ago

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Nov 11, 2024, 4:01 PM EST - 8 months ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 4, 2024, 7:30 AM EST - 8 months ago

Neurogene Announces Oversubscribed $200 Million Private Placement

Oct 21, 2024, 7:30 AM EDT - 9 months ago

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Aug 7, 2024, 7:30 AM EDT - 1 year ago

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Neurogene to Participate in BMO Genetic Medicines Summit

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Neurogene Announces Addition to Russell 3000® Index

Jun 18, 2024, 9:26 AM EDT - 1 year ago

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

May 10, 2024, 7:30 AM EDT - 1 year ago

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

May 7, 2024, 6:19 AM EDT - 1 year ago

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

Apr 22, 2024, 4:36 PM EDT - 1 year ago

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Mar 18, 2024, 4:14 PM EDT - 1 year ago

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Mar 4, 2024, 7:30 AM EST - 1 year ago

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

Feb 29, 2024, 7:30 AM EST - 1 year ago

Neurogene to Participate in Upcoming Investor Conferences

Jan 16, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Jan 5, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Business Update and 2024 Outlook

Mkemovic23 Jul. 9 at 11:46 PM

$NGNE could get the breakout move tomorrow

0 · Reply

MisterRaymond Jul. 9 at 5:50 PM

$NGNE

0 · Reply

Mkemovic23 Jul. 9 at 4:34 PM

$NGNE guess I’ll just enjoy this move myself. 8 days, no posts here besides me. This company could easily run To 30-40 with very little effort and it probably will

0 · Reply

Mkemovic23 Jul. 8 at 4:33 PM

$NGNE great move today, let’s clear 21.8 and there is tremendous upside here … small number of watchers

0 · Reply

topstockalerts Jul. 1 at 7:49 PM

$NGNE Strong move today..👀---👀...

0 · Reply

hiloSF Jul. 1 at 7:26 PM

0 · Reply

topstockalerts Jul. 1 at 7:02 PM

$NGNE strong watch at these levels 👀💪👀

0 · Reply

FelipeLuis Jul. 1 at 6:36 PM

$NGNE Solid news. Can move in any direction anytime. $BGLC $BGL $BMNR

0 · Reply

FelipeLuis Jul. 1 at 6:29 PM

$NGNE Solid news. Just need to hold and wait

0 · Reply

Mkemovic23 Jul. 1 at 6:20 PM

$NGNE can be $30-40 in a blink of an eye, literally no float

0 · Reply

BullsEye2000 Jul. 1 at 6:13 PM

$NGNE this can move violently in any direction but I believe we can see $30+ today

1 · Reply

BullsEye2000 Jul. 1 at 6:10 PM

$NGNE damn the news is solid. I hate bios but FDA news is fairly good.

0 · Reply

MadMaverick Jul. 1 at 5:34 PM

🚨 $DMAC 🚨 Low float. Massive Friday volume. 👀 Once that demand reappears, this could run 10–20% in a flash. Why the buzz? 👇 DMAC is pioneering a novel therapy targeting stroke and preeclampsia, two areas with massive unmet need. The science might just be catching up to the chart. More research about the company https://chartingdaily.com/redefine-possibilities-a-new-treatment-for-preeclampsia-stroke Communicated disclaimer - DYOR $BGLC $NGNE $MBIO

0 · Reply

JFDI Jul. 1 at 5:26 PM

$NGNE island forming.

0 · Reply

themacromindset Jul. 1 at 4:18 PM

$NGNE next targets 60-80$

0 · Reply

topstockalerts Jul. 1 at 3:12 PM

Top Gainers PT2 $VVOS $TLYS $SNGX $NGNE $BGL

0 · Reply

FloatRaider Jul. 1 at 3:00 PM

$NGNE Great looking chart. Nice flag on the 1min 📣 ATER breakout watch Higher lows + tightening range under $1.75—classic setup 🔍 Wall Street sees $4.00 avg (approx. +140%) and bulls eye $8.16 (+400%) Next stop: 2×–4× gains ahead if breakout confirms!

0 · Reply

zombie717 Jul. 1 at 2:52 PM

$NGNE why the pop?

0 · Reply

topstockalerts Jul. 1 at 2:39 PM

$NGNE where’s she going next?? 🏦🚨🏦

0 · Reply

patb99 Jul. 1 at 2:20 PM

$NGNE VWAP under 18$

0 · Reply

patb99 Jul. 1 at 1:57 PM

$NGNE drop is coming

0 · Reply

Stock_Catcher Jul. 1 at 1:54 PM

$NGNE skipping tape up thin name though

0 · Reply

Market Cap	305.64M
Revenue (ttm)	930,000.00
Net Income (ttm)	-75.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,079.57%
Debt to Equity Ratio	0.00

Volume	113,400
Avg Vol	224,054
Day's Range	N/A - N/A
Shares Out	14.26M
Stochastic %K	90%
Beta	1.51
Analysts	Strong Sell
Price Target	$43.83